Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression
Authors:
Open Access
- 1 September 2006
- journal article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 13 (3) , 851-861
Abstract
Oestrogen receptor-α (ERα) is an important prognostic marker in breast cancer and endocrine therapies are designed to inhibit or prevent ERα activity. In vitro studies have indicated that phosphorylation of ERα, in particular on serine 118 (S118), can result in activation in a ligand-independent manner, thereby potentially contributing to resistance to endocrine agents, such as tamoxifen and aromatase inhibitors. Here we report the immunohistochemistry (IHC) of S118 phosphorylation in 301 primary breast tumour biopsies. Surprisingly, this analysis shows that S118 phosphorylation is higher in more differentiated tumours, suggesting that phosphorylation at this site is associated with a good prognosis in patients not previously treated with endocrine agents. However, we also report that S118 phosphorylation was elevated in tumour biopsies taken from patients who had relapsed following tamoxifen treatment, when compared to pre-treatment biopsies. Taken together, these data are consistent with the view that S118 phosphorylation is a feature of normal ERα function and that increases in levels of phosphorylation at this site may play a key role in the emergence of endocrine resistance in breast cancer.Keywords
This publication has 44 references indexed in Scilit:
- Distinct mRNA, protein expression patterns and distribution of oestrogen receptors α and β in human primary breast cancer: Correlation with proliferation marker Ki-67 and clinicopathological factorsEuropean Journal of Cancer, 2005
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- The role of mitogen-activated protein (MAP) kinase in breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2002
- Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancerInternational Journal of Cancer, 2001
- Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patientsInternational Journal of Cancer, 2000
- Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approachThe Journal of Steroid Biochemistry and Molecular Biology, 2000
- Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.The EMBO Journal, 1996
- A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samplesHuman Pathology, 1995
- Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity.Journal of Biological Chemistry, 1994
- Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region.The EMBO Journal, 1993